Literature DB >> 17724450

Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells.

Alexander Meissner1, Marius Wernig, Rudolf Jaenisch.   

Abstract

In vitro reprogramming of somatic cells into a pluripotent embryonic stem cell-like state has been achieved through retroviral transduction of murine fibroblasts with Oct4, Sox2, c-myc and Klf4. In these experiments, the rare 'induced pluripotent stem' (iPS) cells were isolated by stringent selection for activation of a neomycin-resistance gene inserted into the endogenous Oct4 (also known as Pou5f1) or Nanog loci. Direct isolation of pluripotent cells from cultured somatic cells is of potential therapeutic interest, but translation to human systems would be hindered by the requirement for transgenic donors in the present iPS isolation protocol. Here we demonstrate that reprogrammed pluripotent cells can be isolated from genetically unmodified somatic donor cells solely based upon morphological criteria.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17724450     DOI: 10.1038/nbt1335

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  265 in total

Review 1.  Pluripotency of human embryonic and induced pluripotent stem cells for cardiac and vascular regeneration.

Authors:  Kenneth R Boheler
Journal:  Thromb Haemost       Date:  2010-05-10       Impact factor: 5.249

2.  Isolation of undifferentiated and early differentiating type A spermatogonia from Pou5f1-GFP reporter mice.

Authors:  Thomas Garcia; Marie-Claude Hofmann
Journal:  Methods Mol Biol       Date:  2012

Review 3.  Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.

Authors:  Marica Grskovic; Ashkan Javaherian; Berta Strulovici; George Q Daley
Journal:  Nat Rev Drug Discov       Date:  2011-11-11       Impact factor: 84.694

Review 4.  Getting to the heart of myocardial stem cells and cell therapy.

Authors:  Tara L Rasmussen; Ganesh Raveendran; Jianyi Zhang; Daniel J Garry
Journal:  Circulation       Date:  2011-04-26       Impact factor: 29.690

5.  Ca2+ activated K channels-new tools to induce cardiac commitment from pluripotent stem cells in mice and men.

Authors:  Martin Müller; Marianne Stockmann; Daniela Malan; Anne Wolheim; Michael Tischendorf; Leonhard Linta; Sarah-Fee Katz; Qiong Lin; Stephan Latz; Cornelia Brunner; Anna M Wobus; Martin Zenke; Maria Wartenberg; Tobias M Boeckers; Götz von Wichert; Bernd K Fleischmann; Stefan Liebau; Alexander Kleger
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

6.  Molecular insights into the heterogeneity of telomere reprogramming in induced pluripotent stem cells.

Authors:  Fang Wang; Yu Yin; Xiaoying Ye; Kai Liu; Haiying Zhu; Lingling Wang; Maria Chiourea; Maja Okuka; Guangzhen Ji; Jiameng Dan; Bingfeng Zuo; Minshu Li; Qian Zhang; Na Liu; Lingyi Chen; Xinghua Pan; Sarantis Gagos; David L Keefe; Lin Liu
Journal:  Cell Res       Date:  2011-12-20       Impact factor: 25.617

Review 7.  Epigenetic landscape of pluripotent stem cells.

Authors:  Ji Woong Han; Young-sup Yoon
Journal:  Antioxid Redox Signal       Date:  2012-01-11       Impact factor: 8.401

Review 8.  Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs.

Authors:  Chao-Shun Yang; Tariq M Rana
Journal:  Mol Biosyst       Date:  2012-10-05

Review 9.  Mechanisms underlying the formation of induced pluripotent stem cells.

Authors:  Federico González; Danwei Huangfu
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-09-18       Impact factor: 5.814

10.  Human immature dental pulp stem cells' contribution to developing mouse embryos: production of human/mouse preterm chimaeras.

Authors:  S A Siqueira da Fonseca; S Abdelmassih; T de Mello Cintra Lavagnolli; R C Serafim; E J Clemente Santos; C Mota Mendes; V de Souza Pereira; C E Ambrosio; M A Miglino; J A Visintin; R Abdelmassih; A Kerkis; I Kerkis
Journal:  Cell Prolif       Date:  2009-02-24       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.